Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2018-06-07 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2018-06-07 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 6, 2018, by Zafgen, Inc. It reports the departure and election of directors, specifically the resignation of two directors and the election of a new director. It also includes the submission of matters to a vote of security holders at the Annual Meeting, detailing the voting results for director elections and ratification of the independent auditor. The content focuses on changes in the company's board of directors and voting results from the Annual Meeting. There is no detailed financial data or comprehensive report content, but rather announcements about board changes and voting outcomes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The voting results are also included but since the document primarily focuses on director changes and the election, the best fit is MANG. Confidence is high because the document explicitly details director departures and elections, which is the core of MANG filings.
2018-06-07 English
FORM 4 SUBMISSION
Director's Dealing
2018-05-30 English
FORM 3 SUBMISSION
Director's Dealing
2018-05-30 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 25, 2018, reporting the appointment of a new Chief Business Officer, Brian P. McVeigh. It details his background, employment terms, severance and change in control agreements, and includes references to exhibits such as the employment offer letter and severance agreement. The key content is about a change in senior management personnel. There are no financial statements or earnings data, nor is this a report of voting results or a regulatory compliance filing unrelated to management changes. The primary focus is the announcement of a management appointment and related agreements, which fits the category of Board/Management Information (MANG). The document length is over 10,000 characters, so it is not a brief announcement or a report publication announcement. Therefore, the correct classification is MANG with high confidence.
2018-05-30 English
10-Q
Interim / Quarterly Report Q1 2018
2018-05-10 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.